Mercury Laboratories Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, demonstrating adherence to regulatory requirements for securities dematerialisation processes.

Regulatory Compliance Filing

The pharmaceutical company filed the mandatory certificate on April 6, 2026, with BSE Limited through Company Secretary Krishna Shah. The submission fulfills requirements under Regulation 74(5) of Securities Exchange Board of India (Depositories and Participants) Regulations, 2018.

Registrar Confirmation

MUFG Intime India Private Limited, serving as Mercury Laboratories' Registrar and Share Transfer Agent, issued the compliance certificate on April 3, 2026. The registrar confirmed proper handling of securities received from depository participants during the quarter.

Sr. Vice President Ashok Shetty signed the certificate on behalf of MUFG Intime India, confirming that:

• Securities received for dematerialisation were properly confirmed to depositories
• All securities have been listed on relevant stock exchanges
• Security certificates were mutilated and cancelled after verification
• Depository names were substituted in member registers within prescribed timelines

Process Verification

The certificate validates that Mercury Laboratories maintained compliance with SEBI's dematerialisation regulations throughout Q4FY26. The registrar confirmed that all securities comprised in certificates received during the quarter have been listed on stock exchanges where the company's previously issued securities are traded.

Corporate Information

Mercury Laboratories operates from multiple locations including its head office and Factory-1 at Gorwa Industrial Estate, Vadodara, and Factory-2 at Halol-Vadodara Road. The company's registered office is located at Shreeji Bhuvan, Mumbai. MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's registrar from its Mumbai office.

Mercury Laboratories announced its unaudited financial results for the quarter and nine months ended December 31, 2025, presenting a mixed performance scenario. The pharmaceutical company's Board of Directors approved these results during their meeting held on February 11, 2026, in Vadodara, with the meeting commencing at 9:00 AM IST and concluding at 11:15 AM IST.

Quarterly Financial Performance

The company's Q3FY26 performance reflected operational challenges with key metrics showing year-on-year decline. Revenue from operations contracted by 6.2% to ₹1,835.03 lakhs compared to ₹1,957.15 lakhs in Q3FY25. Net profit after tax decreased by 16.4% to ₹99.75 lakhs from ₹119.28 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Shows Recovery

Despite quarterly challenges, the nine-month performance demonstrated significant improvement. Net profit for the nine months ended December 31, 2025, surged by 77.3% to ₹360.84 lakhs compared to ₹203.47 lakhs in the corresponding period of FY25. Revenue from operations also showed growth of 1.9% to ₹5,549.43 lakhs from ₹5,444.21 lakhs.

Operational Expenses and Exceptional Items

The company's total expenses for Q3FY26 decreased to ₹1,683.80 lakhs from ₹1,845.75 lakhs in Q3FY25. Key expense components included cost of materials consumed at ₹629.78 lakhs, employee benefits expense of ₹417.26 lakhs, and other expenses totaling ₹461.97 lakhs. An exceptional item of ₹39.49 lakhs impacted quarterly results, related to gratuity provisions arising from the implementation of new labour codes by the Government of India.

Labour Code Impact and Regulatory Changes

The Government of India notified provisions of the four new labour codes on November 21, 2025, consolidating twenty-nine existing labour laws into a unified framework. The revised definition of wages under these codes resulted in an incremental gratuity impact of ₹39.49 lakhs, which the company presented as an exceptional item in accordance with Ind AS 19 Employee Benefits.

Regulatory Compliance and Financial Position

Mercury Laboratories submitted these results to BSE Limited under Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company maintained a stable financial position with paid-up equity share capital of ₹120.00 lakhs, consisting of shares with a face value of ₹10 each. The statutory auditors conducted a limited review of the financial results, and the company operates in a single segment focused on pharmaceutical products.